Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Three Arm, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of RZL-012 in Subjects Seeking for Submental Fat Reduction

NCT04867434 is registered in ClinicalTrials.gov with Raziel Therapeutics Ltd. as lead sponsor.

NCT NCT04867434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04867434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Three Arm, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of RZL-012 in Subjects Seeking for Submental Fat Reduction
Lead sponsor
Raziel Therapeutics Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2021
Completion date
May 31, 2022
Enrollment
151 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

submental fat